stockrow
Saturday 7 November 2026
Export PBYI’s income statement to Excel — free account
Puma Biotechnology, Inc.
PBYI Healthcare Biotechnology
Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024.
- Revenue
- +7.75%
- EPS
- +33.3%
- Free cash flow
- −88.5%
- Total debt
- −79.8%
Quarter to June 2026, against a year earlier
8.27
1.50
−15.35%
Follow PBYI
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
15.02 | 12.78 | 9.44 | 7.08 |
+8 more quarters Free account |
P/S ratio |
1.79 | 1.43 | 1.30 | 1.26 | |
P/FCF ratio |
14.46 | 7.92 | 10.18 | 8.80 | |
P/Operating CF |
254.39 | 21.08 | 20.64 | 27.59 | |
P/B ratio |
2.98 | 2.53 | 2.28 | 2.32 | |
Price to Tangible BV |
4.05 | 3.63 | 3.35 | 3.74 | |
EV/Sales |
1.48 | 1.07 | 1.01 | 1.02 | |
EV/EBITDA |
8.34 | 6.05 | 4.80 | 4.82 | |
EV/Operating CF |
8.30 | 4.54 | 5.53 | 5.01 | |
EV/FCF |
11.95 | 5.93 | 7.91 | 7.09 | |
Quick Ratio |
2.57 | 2.18 | 1.89 | 1.57 | |
Current Ratio |
2.91 | 2.38 | 2.00 | 1.74 | |
Net Debt/EBITDA |
(9.30) | 74.24 | (3.90) | (5.10) | |
Debt/Assets |
0.00% | 5.86% | 10.41% | 16.62% | |
Debt/Equity |
0.00 | 0.09 | 0.17 | 0.29 | |
Asset Turnover |
1.19 | 1.17 | 1.06 | 1.00 | |
Operating CF/Net income |
0.20 | (4.11) | 1.07 | 1.10 | |
Capex/Depreciation |
0.00 | 0.00 | 0.01 | (0.01) | |
Interest Coverage |
42.14 | (5.24) | 15.29 | 6.43 | |
Research and Development Expense of Revenue |
33.44% | 44.17% | 22.32% | 29.21% | |
Selling, General and Administrative Expense of Revenue |
31.06% | 41.11% | 24.36% | 30.87% | |
Intangible Assets out of Total Assets |
0.19 | 0.20 | 0.19 | 0.22 | |
Share Based Compensation of Revenue |
3.46% | 4.23% | 2.14% | 3.07% | |
Graham Net Nets |
0.22 | 0.24 | 0.26 | 0.21 | |
Graham Number |
5.75 | 5.33 | 6.08 | 6.22 | |
Earnings Yield |
6.66% | 7.82% | 10.59% | 14.12% | |
Free Cash Flow Yield |
6.92% | 12.63% | 9.82% | 11.36% | |
Revenue per Share |
1.11 | 0.88 | 1.51 | 1.08 | |
Operating CF per Share |
0.03 | 0.30 | 0.29 | 0.19 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.03 | 0.30 | 0.29 | 0.19 | |
Cash per Share |
1.84 | 2.04 | 1.99 | 1.92 | |
Shareholders Equity per Share |
2.72 | 2.53 | 2.61 | 2.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.72 | 2.53 | 2.61 | 2.29 | |
Free Cash Flow |
1.62 | 15.42 | 14.46 | 9.66 | |
Working Capital |
95.25 | 82.52 | 81.43 | 60.85 | |
Capital Expenditures |
— | — | 0.04 | (0.03) | |
Net Current Asset Value |
90.88 | 77.98 | 76.72 | 55.99 | |
EV/EBIT |
11.22 | 8.26 | 6.20 | 6.42 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
13.57 | 11.02 | 7.98 | 7.97 | |
| Other line items | |||||
Average Receivables |
29.99 | 25.75 | 42.83 | 44.10 | |
Average Payables |
4.26 | 7.10 | 5.28 | 6.95 | |
Average Inventory |
10.96 | 8.72 | 7.12 | 6.07 | |
Average Assets |
193.83 | 194.44 | 214.82 | 211.79 | |
Average Common Equity |
121.63 | 112.76 | 111.23 | 93.18 |
Columns are period end dates